Antimicrobial peptide with activity against Gram-positive bacterial strains (S.aureus (MIC=2-140 uM), methicillin-resistant S.aureus (MRSA) (MIC=8-17 uM), S.epidermidis (MIC=1.17 uM), and the yeasts C.albicans, C.krusei, and C.glabrata (MIC=34-69 uM)) (PubMed:25805002, PubMed:27567704, PubMed:29670004, PubMed:30709056). Acts by disrupting the cell membrane (observed on outer layer of the S.aureus) (PubMed:30709056). Is not active against Gram-negative bacteria (E.coli, E.Cloacae, P.aeruginosa), and the Gram-positive bacterium E.faecalis (PubMed:25805002, PubMed:27567704, PubMed:29670004, PubMed:30709056). Also shows toxicity against several cell lines, but possess low hemolytic activity at the highest concentration tested (PubMed:25805002, PubMed:29670004, PubMed:30709056). Also shows antiparasitic activity against Trypanosoma cruzi by decreasing the viability of the epimastigote and trypomastigote forms of the parasite (PubMed:29670004, PubMed:30709056). Displays high hydroxyl radical scavenging activity (antioxidant action) (PubMed:33359395). In a wound infection model, the topical application of this peptide demonstrates antibacterial effects, as well as an ability to accelerate wound closure speed, which suggests the induction of tissue repair (PubMed:33359395). In the model of polymicrobial sepsis, it exhibits an antibiotic effect, reducing the levels of microorganisms in the infectious focus and the inflammatory responses in the lung and cecum of septic animals (PubMed:27567704). Stable to pH variation. Expressed by the venom gland. Belongs to the non-disulfide-bridged peptide (NDBP) superfamily. Short antimicrobial peptide (group 4) family.